Cargando…

Ursodeoxycholic acid potentiates dipeptidyl peptidase-4 inhibitor sitagliptin by enhancing glucagon-like peptide-1 secretion in patients with type 2 diabetes and chronic liver disease: a pilot randomized controlled and add-on study

OBJECTIVE: We evaluated the effects of ursodeoxycholic acid (UDCA) on glucagon-like peptide-1 (GLP-1) secretion and glucose tolerance in patients with type 2 diabetes with chronic liver disease. RESEARCH DESIGN AND METHODS: Japanese patients with type 2 diabetes (glycated hemoglobin (HbA1c) levels ≥...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shima, Kosuke Robert, Ota, Tsuguhito, Kato, Ken-ichiro, Takeshita, Yumie, Misu, Hirofumi, Kaneko, Shuichi, Takamura, Toshinari
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Emerging Technologies, Pharmacology and Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5873545/ https://www.ncbi.nlm.nih.gov/pubmed/29607050 http://dx.doi.org/10.1136/bmjdrc-2017-000469

Ejemplares similares

Inverse Correlation between Serum Levels of Selenoprotein P and Adiponectin in Patients with Type 2 Diabetes
por: Misu, Hirofumi, et al.
Publicado: (2012)

Ectopic Fat Accumulation and Distant Organ-Specific Insulin Resistance in Japanese People with Nonalcoholic Fatty Liver Disease
por: Kato, Ken-ichiro, et al.
Publicado: (2014)

Vildagliptin vs liraglutide as a second-line therapy switched from sitagliptin-based regimens in patients with type 2 diabetes: A randomized, parallel-group study
por: Takeshita, Yumie, et al.
Publicado: (2015)

Liver steatosis is associated with insulin resistance in skeletal muscle rather than in the liver in Japanese patients with non-alcoholic fatty liver disease
por: Kato, Ken-ichiro, et al.
Publicado: (2015)

Fat‐free mass and calf circumference as body composition indices to determine non‐exercise activity thermogenesis in patients with diabetes
por: Isobe, Yuki, et al.
Publicado: (2015)

Mealtime dosing of a rapid-acting insulin analog reduces glucose variability and suppresses daytime cardiac sympathetic activity: a randomized controlled study in hospitalized patients with type 2 diabetes
por: Kanamori, Takehiro, et al.
Publicado: (2018)

Effects of metformin and alogliptin on body composition in people with type 2 diabetes
por: Takeshita, Yumie, et al.
Publicado: (2018)

Inhibition of Dipeptidyl Peptidase-4 by Vildagliptin During Glucagon-Like Peptide 1 Infusion Increases Liver Glucose Uptake in the Conscious Dog
por: Edgerton, Dale S., et al.
Publicado: (2009)

Sitagliptin versus mitiglinide switched from mealtime dosing of a rapid-acting insulin analog in patients with type 2 diabetes: a randomized, parallel-group study
por: Takeshita, Yumie, et al.
Publicado: (2015)

Nature of action of Sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animals
por: Davis, Joseph A., et al.
Publicado: (2010)

Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study)
por: Nomoto, Hiroshi, et al.
Publicado: (2022)

Bending of a vertical cannula without alarm during insulin pump therapy as a cause of unexpected hyperglycemia: A Japanese issue?
por: Kuroda, Kaori, et al.
Publicado: (2015)

Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin
por: Wilson, Jessica R., et al.
Publicado: (2017)

Dipeptidyl peptidase-4 inhibition by Saxagliptin prevents inflammation and renal injury by targeting the Nlrp3/ASC inflammasome
por: Birnbaum, Yochai, et al.
Publicado: (2016)

Renoprotective effects of atorvastatin compared with pravastatin on progression of early diabetic nephropathy
por: Takazakura, Akiko, et al.
Publicado: (2015)

Palmitate Induces Insulin Resistance in H4IIEC3 Hepatocytes through Reactive Oxygen Species Produced by Mitochondria
por: Nakamura, Seiji, et al.
Publicado: (2009)

Impact of glucagon-like peptide 1 receptor agonist liraglutide and dipeptidyl peptidase-4 inhibitor sitagliptin on bowel cleaning and gastrointestinal symptoms in type 2 diabetes
por: Tong, Yan, et al.
Publicado: (2023)

Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin
por: Tatosian, Daniel A., et al.
Publicado: (2013)

The Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Improves Vascular Endothelial Function in Type 2 Diabetes
por: Kubota, Yoshiaki, et al.
Publicado: (2012)

Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes
por: Mega, Cristina, et al.
Publicado: (2017)

Metformin Prevents and Reverses Inflammation in a Non-Diabetic Mouse Model of Nonalcoholic Steatohepatitis
por: Kita, Yuki, et al.
Publicado: (2012)

CD26/dipeptidyl peptidase IV enhances expression of topoisomerase II alpha and sensitivity to apoptosis induced by topoisomerase II inhibitors
por: Sato, K, et al.
Publicado: (2003)

Effect of CD26/dipeptidyl peptidase IV on Jurkat sensitivity to G(2)/M arrest induced by topoisomerase II inhibitors
por: Aytac, U, et al.
Publicado: (2003)

Effects of metformin, acarbose, and sitagliptin monotherapy on gut microbiota in Zucker diabetic fatty rats
por: Zhang, Minchun, et al.
Publicado: (2019)

Severe edema and blood blisters of the lower extremities caused by sitagliptin, a dipeptidyl peptidase‐4 inhibitor
por: Maita, Hiroki, et al.
Publicado: (2021)

Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Phosphate Accelerates Cellular Cholesterol Efflux in THP-1 Cells
por: Komatsu, Tomohiro, et al.
Publicado: (2023)

Association between Add-On Dipeptidyl Peptidase-4 Inhibitor Therapy and Diabetic Retinopathy Progression
por: Kang, Eugene Yu-Chuan, et al.
Publicado: (2021)

Insulin–glucagon‐like peptide‐1 receptor agonist relay and glucagon‐like peptide‐1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open‐label trial study
por: Takeshita, Yumie, et al.
Publicado: (2022)

Pleiotropic effects of sitagliptin versus voglibose in patients with type 2 diabetes inadequately controlled via diet and/or a single oral antihyperglycemic agent: a multicenter, randomized trial
por: Matsushima, Yukiko, et al.
Publicado: (2016)

Effect of Repeated Glucagon Doses on Hepatic Glycogen in Type 1 Diabetes: Implications for a Bihormonal Closed-Loop System
por: Castle, Jessica R., et al.
Publicado: (2015)

p62‐mediated autophagy affects nutrition‐dependent insulin receptor substrate 1 dynamics in 3T3‐L1 preadipocytes
por: Igawa, Hirobumi, et al.
Publicado: (2018)

Response to Letter to the Editor: “Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin”
por: Wilson, Jessica R, et al.
Publicado: (2020)

Proteasome Dysfunction Mediates Obesity-Induced Endoplasmic Reticulum Stress and Insulin Resistance in the Liver
por: Otoda, Toshiki, et al.
Publicado: (2013)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

Concentration-dependent Dual Effects of Hydrogen Peroxide on Insulin Signal Transduction in H4IIEC Hepatocytes
por: Iwakami, Satoshi, et al.
Publicado: (2011)

Effect of a Dipeptidyl Peptidase-IV Inhibitor, Des-Fluoro-Sitagliptin, on Neointimal Formation after Balloon Injury in Rats
por: Lim, Soo, et al.
Publicado: (2012)

The Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Protects against Dyslipidemia-Related Kidney Injury in Apolipoprotein E Knockout Mice
por: Li, Jingjing, et al.
Publicado: (2014)

Dipeptidyl-Peptidase 4 Inhibitor Sitagliptin Ameliorates Hepatic Insulin Resistance by Modulating Inflammation and Autophagy in ob/ob Mice
por: Zheng, Wenbin, et al.
Publicado: (2018)

Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Muscle Mass and the Muscle/Fat Ratio in Patients With Type 2 Diabetes
por: Ishii, Satoshi, et al.
Publicado: (2020)

Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus()
por: Van Gaal, Luc, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qgs37ihove8bq7j8unj647j4t0